← Back to Search

Overdose Prevention Intervention for Drug Overdose (Oasis Trial)

N/A
Recruiting
Led By Carl Latkin, PhD
Research Sponsored by Johns Hopkins Bloomberg School of Public Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Any mental or physical health impairment that impedes ability to participate
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a targeted, peer-driven intervention can reduce HIV and HCV transmission, as well as overdose risk behaviors, among people who inject drugs.

Who is the study for?
This trial is for current opioid users who have used within the last two weeks. It's aimed at people who inject drugs and are at risk of HIV, hepatitis C, or drug overdose. Participants must be able to engage in the study without mental or physical health issues interfering.
What is being tested?
The study tests a new peer-driven intervention designed to reduce the risks of HIV, hepatitis C virus transmission, and overdoses among those who inject drugs. It's a pilot program focusing on injection settings.
What are the potential side effects?
Since this is an educational and behavioral intervention rather than a medication-based one, traditional side effects like you'd see with drugs aren't expected. However, participants may experience stress or emotional discomfort.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any health issues that prevent me from participating.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
HIV/HCV prevention
Overdose prevention
Secondary study objectives
Overdose behaviors
Overdose behaviors 2

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ExperimentalExperimental Treatment1 Intervention
behavioral training with 6 sessions
Group II: comparisonActive Control1 Intervention
Attention control

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,587 Previous Clinical Trials
3,328,263 Total Patients Enrolled
Johns Hopkins Bloomberg School of Public HealthLead Sponsor
427 Previous Clinical Trials
2,133,417 Total Patients Enrolled
Carl Latkin, PhDPrincipal InvestigatorJohns Hopkins Bloomberg School of Public Health
5 Previous Clinical Trials
4,042 Total Patients Enrolled

Media Library

HIV, HCV and overdose prevention Clinical Trial Eligibility Overview. Trial Name: NCT05320835 — N/A
Human Immunodeficiency Virus Infection Research Study Groups: Experimental, comparison
Human Immunodeficiency Virus Infection Clinical Trial 2023: HIV, HCV and overdose prevention Highlights & Side Effects. Trial Name: NCT05320835 — N/A
HIV, HCV and overdose prevention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05320835 — N/A
~80 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top